These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 16087398

  • 1. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A, Iversen PL.
    Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
    [Abstract] [Full Text] [Related]

  • 2. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation.
    Iversen PL.
    Curr Opin Mol Ther; 2001 Jun; 3(3):235-8. PubMed ID: 11497346
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.
    Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM.
    Bioconjug Chem; 2005 Jun; 16(4):959-66. PubMed ID: 16029037
    [Abstract] [Full Text] [Related]

  • 7. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
    Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL.
    Clin Cancer Res; 2005 May 15; 11(10):3930-8. PubMed ID: 15897595
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
    Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, Iversen PL, Lebleu B.
    J Control Release; 2006 Dec 01; 116(3):304-13. PubMed ID: 17097177
    [Abstract] [Full Text] [Related]

  • 11. Five-step process for screening antisense compounds for efficacy: gene target IL-12Rb2.
    Marshall NB, Hauck LL, Mourich DV.
    Methods Mol Biol; 2011 Dec 01; 764():153-68. PubMed ID: 21748639
    [Abstract] [Full Text] [Related]

  • 12. Toxicology of antisense therapeutics.
    Jason TL, Koropatnick J, Berg RW.
    Toxicol Appl Pharmacol; 2004 Nov 15; 201(1):66-83. PubMed ID: 15519609
    [Abstract] [Full Text] [Related]

  • 13. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ, Anastasopoulos F, Pouton CW, Boyd BJ.
    Expert Rev Mol Med; 2009 Mar 23; 11():e10. PubMed ID: 19302730
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate.
    Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, Youngblood DS, Iversen PL.
    Bioconjug Chem; 2007 Mar 23; 18(4):1325-31. PubMed ID: 17583927
    [Abstract] [Full Text] [Related]

  • 15. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.
    Sekhon HS, London CA, Sekhon M, Iversen PL, Devi GR.
    Lung Cancer; 2008 Jun 23; 60(3):347-54. PubMed ID: 18096271
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.
    Gene Ther; 2006 Oct 23; 13(19):1373-81. PubMed ID: 16724091
    [Abstract] [Full Text] [Related]

  • 20. Antisense treatments for biothreat agents.
    Warfield KL, Panchal RG, Aman MJ, Bavari S.
    Curr Opin Mol Ther; 2006 Apr 23; 8(2):93-103. PubMed ID: 16610760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.